Literature DB >> 30129037

The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.

Revathy Carnagarin1, Vance Matthews1, Maria T K Zaldivia2,3, Karlheinz Peter2,3, Markus P Schlaich1,4,5.   

Abstract

Over the last few years, evidence has accumulated to suggest that hypertension is, at least in part, an immune-mediated inflammatory disorder. Many links between immunity and hypertension have been established and provide a complex framework of mechanistic interactions contributing to the rise in BP. These include immune-mediated inflammatory processes affecting regulatory brain nuclei and interactions with other mediators of cardiovascular regulation such as the sympathetic nervous system. Sympathoexcitation differentially regulates T-cells based upon activation status of the immune cell as well as the resident organ. Exogenous and endogenous triggers activate signalling pathways in innate and adaptive immune cells resulting in pro-inflammatory cytokine production and activation of T-lymphocytes in the cardiovascular and renal regions, now considered major factors in the development of essential hypertension. The inflammatory cascade is sustained and exacerbated by the immune flow via the brain-bone marrow-spleen-gastrointestinal axis and thereby further aggravating immune-mediated pathways resulting in a vicious cycle of established hypertension and target organ damage. This review summarizes the evidence and recent advances in linking immune-mediated inflammation, sympathetic activation and their bidirectional interactions with the development of hypertension. LINKED ARTICLES: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2018        PMID: 30129037      PMCID: PMC6534787          DOI: 10.1111/bph.14481

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  166 in total

Review 1.  Beta-adrenergic receptors in congestive heart failure: present knowledge and future directions.

Authors:  A S Maisel; M C Michel
Journal:  Cardiology       Date:  1989       Impact factor: 1.869

2.  T regulatory lymphocytes prevent aldosterone-induced vascular injury.

Authors:  Daniel A Kasal; Tlili Barhoumi; Melissa W Li; Naoki Yamamoto; Evguenia Zdanovich; Asia Rehman; Mario F Neves; Pascal Laurant; Pierre Paradis; Ernesto L Schiffrin
Journal:  Hypertension       Date:  2011-12-05       Impact factor: 10.190

3.  α1-adrenergic receptors positively regulate Toll-like receptor cytokine production from human monocytes and macrophages.

Authors:  Laurel A Grisanti; Andrew P Woster; Julie Dahlman; Edward R Sauter; Colin K Combs; James E Porter
Journal:  J Pharmacol Exp Ther       Date:  2011-05-13       Impact factor: 4.030

4.  Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit.

Authors:  Mauricio Rosas-Ballina; Peder S Olofsson; Mahendar Ochani; Sergio I Valdés-Ferrer; Yaakov A Levine; Colin Reardon; Michael W Tusche; Valentin A Pavlov; Ulf Andersson; Sangeeta Chavan; Tak W Mak; Kevin J Tracey
Journal:  Science       Date:  2011-09-15       Impact factor: 47.728

5.  Evolution of renal interstitial inflammation and NF-kappaB activation in spontaneously hypertensive rats.

Authors:  Bernardo Rodríguez-Iturbe; Yasmir Quiroz; Atilio Ferrebuz; Gustavo Parra; Nosratola D Vaziri
Journal:  Am J Nephrol       Date:  2004-11-23       Impact factor: 3.754

6.  Altered inflammatory response is associated with an impaired autonomic input to the bone marrow in the spontaneously hypertensive rat.

Authors:  Jasenka Zubcevic; Joo Yun Jun; Seungbum Kim; Pablo D Perez; Aqeela Afzal; Zhiying Shan; Wencheng Li; Monica M Santisteban; Wei Yuan; Marcelo Febo; Jay Mocco; Yumei Feng; Edward Scott; David M Baekey; Mohan K Raizada
Journal:  Hypertension       Date:  2013-12-23       Impact factor: 10.190

Review 7.  The chemokine (C-C motif) ligand 2 in neuroinflammation and neurodegeneration.

Authors:  José L M Madrigal; Javier R Caso
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

8.  Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension.

Authors:  Germán E González; Nour-Eddine Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Yunhe Liu; Pablo Leung; Xiangguo Dai; Xiao-Ping Yang; Edward L Peterson; Oscar A Carretero
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

9.  Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.

Authors:  Meena S Madhur; Heinrich E Lob; Louise A McCann; Yoichiro Iwakura; Yelena Blinder; Tomasz J Guzik; David G Harrison
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

10.  Chronic variable stress activates hematopoietic stem cells.

Authors:  Timo Heidt; Hendrik B Sager; Gabriel Courties; Partha Dutta; Yoshiko Iwamoto; Alex Zaltsman; Constantin von Zur Muhlen; Christoph Bode; Gregory L Fricchione; John Denninger; Charles P Lin; Claudio Vinegoni; Peter Libby; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Nat Med       Date:  2014-06-22       Impact factor: 53.440

View more
  9 in total

1.  Immunity and hypertension: New targets to lighten the pressure.

Authors:  Antony Vinh; Grant R Drummond; Christopher G Sobey
Journal:  Br J Pharmacol       Date:  2019-06       Impact factor: 8.739

Review 2.  The bidirectional interaction between the sympathetic nervous system and immune mechanisms in the pathogenesis of hypertension.

Authors:  Revathy Carnagarin; Vance Matthews; Maria T K Zaldivia; Karlheinz Peter; Markus P Schlaich
Journal:  Br J Pharmacol       Date:  2018-09-25       Impact factor: 8.739

Review 3.  Chemoattraction and Recruitment of Activated Immune Cells, Central Autonomic Control, and Blood Pressure Regulation.

Authors:  Khalid Elsaafien; Willian S Korim; Anthony Setiadi; Clive N May; Song T Yao
Journal:  Front Physiol       Date:  2019-08-02       Impact factor: 4.566

Review 4.  Sympathetic Activation in Hypertensive Chronic Kidney Disease - A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?

Authors:  Márcio Galindo Kiuchi; Jan K Ho; Janis Marc Nolde; Leslie Marisol Lugo Gavidia; Revathy Carnagarin; Vance B Matthews; Markus P Schlaich
Journal:  Front Physiol       Date:  2020-01-14       Impact factor: 4.566

Review 5.  Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases: The Heart of the Matter.

Authors:  Stefan Chiriac; Carol Stanciu; Irina Girleanu; Camelia Cojocariu; Catalin Sfarti; Ana-Maria Singeap; Tudor Cuciureanu; Laura Huiban; Cristina Maria Muzica; Sebastian Zenovia; Robert Nastasa; Anca Trifan
Journal:  Can J Gastroenterol Hepatol       Date:  2021-01-12

Review 6.  Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.

Authors:  Revathy Carnagarin; Kearney Tan; Leon Adams; Vance B Matthews; Marcio G Kiuchi; Leslie Marisol Lugo Gavidia; Gavin W Lambert; Elisabeth A Lambert; Lakshini Y Herat; Markus P Schlaich
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

7.  Effect and mechanism of propranolol on promoting osteogenic differentiation and early implant osseointegration.

Authors:  Yupeng Wu; Qi Zhang; Baodong Zhao; Xiaojing Wang
Journal:  Int J Mol Med       Date:  2021-08-20       Impact factor: 4.101

Review 8.  Dysfunction of the Autonomic Nervous System and its Role in the Pathogenesis of Septic Critical Illness (Review).

Authors:  Y Y Kiryachkov; S A Bosenko; B G Muslimov; M V Petrova
Journal:  Sovrem Tekhnologii Med       Date:  2020-08-27

Review 9.  Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.

Authors:  Lakshini Y Herat; Jennifer Matthews; Omar Azzam; Markus P Schlaich; Vance B Matthews
Journal:  Curr Hypertens Rep       Date:  2022-03-02       Impact factor: 5.369

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.